By Staff, Trim Truth Reviews Ingredients Fibre

Glucomannan, reviewed against its own authorised claim

One of the few weight-management ingredients with a specific authorised health claim behind it in Europe — and a set of conditions a buyer can check against the label.

Glucomannan, reviewed against its own authorised claim

Most of what this site reviews is an ingredient with a study behind it and a marketing department in front of it. Glucomannan is different, and it is worth spending a review on precisely because of that difference: it is one of the few things in this category with a specific, published, conditional health claim authorised in Europe.

Updated 7 November 2026: details are re-sourced to primary documents, and lines with no primary document are cut.

Updated 6 November 2026: details corrected against the documents listed below.

Updated 6 November 2026: the score is removed; this is now an assessment of published documents, listed below.

That authorisation is also the best tool a buyer has for judging the products built around it — because the conditions attached to it are strict, and they can be checked on a label.

What was authorised, and on what terms

Read the amount and context rows again, because those are the conditions a label can be checked against.

The claim is conditional on an energy-restricted diet. It is not a claim that this fibre causes weight loss on its own, and the authorised wording says so explicitly. Any product presenting glucomannan as a standalone mechanism has departed from the only claim it is entitled to make.

And the amount is 3 g a day, split into three. That is a substantial quantity of a bulking fibre, and it is the single most useful number in this review.

How products measure up

The arithmetic is unforgiving and takes about ten seconds.

Find the glucomannan content per serving on the panel. Multiply by the servings per day the label directs. The Regulation requires 1 g of glucomannan per quantified portion and that the consumer be told the effect comes from 3 g a day; if the label’s directed servings do not reach 3 g, the product is not delivering the amount it has to tell consumers the effect needs.

Whether a given product reaches 3 g at its directed servings is a label calculation the buyer can make; none of the documents read reports on the market as a whole.

This is the useful thing about an authorised claim with conditions attached: it converts a vague marketing question into arithmetic.

The practical drawbacks, honestly

Even a product that hits the conditions has real trade-offs, and they are not trivial.

The water instruction is a safety instruction, not a suggestion. Glucomannan is a bulking fibre that takes up water, and the authorised conditions carry a choking warning, which is why the water instruction matters. Anyone with a swallowing difficulty or a history of gastrointestinal obstruction should not be self-prescribing a bulking fibre; that is a conversation for a clinician.

Tolerability. EFSA’s 2017 re-evaluation of konjac glucomannan reports gastrointestinal discomfort (laxative effects, flatulence, distension) in clinical studies, and abdominal discomfort including diarrhoea or constipation in several individuals at 3 g a day for 12 weeks.

Timing is demanding. Three separate doses, before meals, each with water, every day, alongside a restricted diet. Adherence to that is a real cost.

It may affect absorption of other things taken at the same time. The EFSA opinion quotes an earlier EU scientific committee noting an effect on vitamin absorption after high doses. This desk read no document on medicines, so if you take medication that is a straightforward reason to ask a pharmacist.

And the honest headline caveat: the claim is about a contribution within an energy-restricted diet. The energy-restricted diet is doing work here. We are not going to tell you how much weight anything will produce, because nobody can.

In the US, the FDA’s dietary supplements page says manufacturers and distributors are responsible for evaluating safety and labelling before marketing. These products are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice.

Pros and cons

Our assessment

This is an assessment of published documents, not of using any product: the most checkable ingredient in a category that resists checking. Its authorised claim is real, specific and conditional, and the label arithmetic shows whether a product delivers the amount it requires.

Our advice on glucomannan is narrower than usual, because for once we can be precise. If you are going to buy it, buy a product that delivers 3 g a day at the label’s own directed servings, follow the water instruction as written, and understand that the authorised claim describes a contribution within an energy-restricted diet and nothing more than that. If a product mentions the claim and the arithmetic does not reach 3 g, you have learned something about the brand rather than about the fibre.

Documents read

Read on 6 November 2026:

  • Commission Regulation (EU) No 432/2012 (EUR-Lex): glucomannan (konjac mannan) in an energy-restricted diet contributes to weight loss: the claim may be used only for food containing 1 g of glucomannan per quantified portion, and the consumer must be told the effect comes from 3 g a day in three doses of 1 g, with 1-2 glasses of water, before meals, in an energy-restricted diet.

  • FDA, Dietary Supplements: manufacturers and distributors are prohibited from marketing adulterated or misbranded supplements and are responsible for evaluating safety and labelling before marketing.

  • GB nutrition and health claims register page (gov.uk): the GB NHC register sets out all authorised and rejected claims and only authorised claims in it may be used in Great Britain.

  • EFSA re-evaluation of konjac gum and konjac glucomannan (E 425), 2017, via PMC: After 3,000 mg a day in adults for 12 weeks, several individuals had abdominal discomfort including diarrhoea or constipation; clinical studies report gastrointestinal di.

← Back to all essays